Eliem Therapeutics Inc. is a clinical-stage biopharmaceutical company that was founded in 2018 and is headquartered in Morrisville, North Carolina. The company is focused on developing novel therapies for the treatment of acute and chronic pain. Eliem Therapeutics is committed to improving the lives of patients who suffer from pain by providing them with safe and effective treatment options.
Eliem Therapeutics is focused on developing therapies that are designed to be effective in treating pain without the risk of addiction or other serious side effects. The company's lead product candidate, ETX-810, is a non-opioid therapy that targets the calcium channel alpha-2-delta-1 subunit to reduce pain signals in the central nervous system. Eliem Therapeutics is also developing a pipeline of other product candidates that target various pain pathways.
Eliem Therapeutics has a strong team of experienced executives and scientists who are dedicated to advancing the company's mission. The company's leadership team has a proven track record of developing and commercializing successful therapies in the pain management space.
Eliem Therapeutics has received funding from several sources, including venture capital firms and government agencies. The company has also entered into partnerships and collaborations with other organizations in the industry to advance its research and development efforts.